New pill shows promise in slowing advanced breast cancer

NCT ID NCT06301438

Recruiting now Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a drug called dalpiciclib in people with a specific type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how long the drug can keep the cancer from growing and what side effects it causes. About 103 participants will take dalpiciclib as a pill for 21 days on, 7 days off. Researchers will track disease progression and any adverse events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dalpiciclib (a CDK4/6 inhibitor taken as a pill)
What this could lead to: If successful, this study could show that dalpiciclib helps control advanced breast cancer for longer, offering a new treatment option for people with this type of cancer.
What could go wrong: This is a real-world study, not a controlled trial, so results may be less reliable. The drug may not work for everyone and can cause side effects like low blood cell counts or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITING

Shanghai, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.